Compare BFST & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFST | OMER |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.1M | 772.8M |
| IPO Year | 2014 | 2008 |
| Metric | BFST | OMER |
|---|---|---|
| Price | $28.48 | $9.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $32.75 | $32.50 |
| AVG Volume (30 Days) | 151.2K | ★ 1.7M |
| Earning Date | 04-27-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | 23.45 | ★ 98.15 |
| EPS | ★ 0.68 | 0.62 |
| Revenue | $10,704,000.00 | ★ $29,868,000.00 |
| Revenue This Year | $22.71 | N/A |
| Revenue Next Year | $5.02 | $233.22 |
| P/E Ratio | $41.84 | ★ $15.79 |
| Revenue Growth | ★ 1.20 | N/A |
| 52 Week Low | $22.56 | $2.95 |
| 52 Week High | $30.32 | $17.65 |
| Indicator | BFST | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 58.65 | 26.75 |
| Support Level | $26.73 | $9.54 |
| Resistance Level | $29.44 | $11.81 |
| Average True Range (ATR) | 0.55 | 0.58 |
| MACD | 0.08 | -0.23 |
| Stochastic Oscillator | 86.32 | 6.51 |
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.